Considering that amphiregulin has been proposed as a biomarker for breast cancer [4], understanding Monad-amphiregulin axis in breast cancer may lead to the development of additional targeted agents to suppress this axis, and result in improved treatments for metastatic breast cancer. Here, AREG is linked to breast carcinoma.